Abstract
for the RCE
Bacillus
anthracis Host
Interactions
Discovery
of Subunit Vaccine Candidates against
Glanders
Alphavirus
Vaccines for Biodefense
Novel
Genetic Tools for Viral Biodefense
Development
and Evaluation of Human
Brucellosis
Vaccines
Rapid
Diagnostic Tools for Q Fever
New
Diagnostic Methods for Accute Rickettsial
Infections
Risks
and Interventions for Pandemic Influenza
Development
of Novel Pseudoinfectious Flavivirus Vaccines
Development
of Diagnostic Reagents for the detection
of
Francisella and
Francisella
Infection
Toward
Control of Rift Valley Fever Virus
Replication
Novel
Vaccine Technology for Biodefense
Nucleocapsid-specific
Small Molecule Inhibitors
of
the Bunyaviridae
New
Technologies for Creating Affinity Reagents
New Opportunities Projects
Identification
and Characterization of Novel
Flavivirus
Antivirals
Biosafety
Containment Training Program
Passive
Immunotherapeutics for
Select
Agents
Preclinical
Testing of YF17D/LAS, a Bivalent
Vaccine
for Lassa and
Yellow
Fever
|
Novel
Genetic Tools for Viral Biodefense
Institution: University of Texas Medical Branch at Galveston (UTMB), Galveston,
TX
Principal Investigator: Peter Mason, Ph.D.
Title of the Project: Novel Genetic Tools
for Viral Biodefense
Co-Investigators:
a) Ilya V. Frolov, Ph.D. – UTMB, Galveston, TX
b) Robert A. Davey, Ph.D. – UTMB, Galveston, TX
Expected Product: Tools
(antiviral screening and diagnostic methods) for identifying
antiviral drugs and diagnosis systems for BWT viruses.
Description: Among pathogens considered likely agents of biological
warfare and terrorism (BWT), RNA viruses comprise many of the most
amenable for use as weapons. With modest cell culture capacity,
large amounts of these viruses can be produced and lyophilized
to generate stockpiles of aerosol-infectious material. Many of
these viruses are readily available from natural sources, increasing
the risk of acquisition by terrorists or governments seeking biological
weapons of mass destruction. For these and other reasons, the viruses
we propose to study are Category A-C agents, and many are also
categorized as select agents by the Centers for Disease Control
and Prevention.
Current defense against most BWT RNA viruses is ineffective or
non-existent. Ribavirin and interferon are effective against a
few BWT RNA viruses but only if administered early during the course
of disease, usually before severe disease is apparent; no effective
therapy exists for later stages of infection when severe signs
such as hemorrhage and encephalitis are first recognized. No licensed
vaccines are available for any of the RNA viruses likely to be
deployed for biological terrorism or warfare. Furthermore, diagnostic
methods for detecting and characterizing human infection can be
slow and imprecise.
We therefore propose to exploit recent advances in RNA virus genetics,
as well as the unique virology expertise within our regional group,
to 1) develop cross-cutting, low containment, rapid and high-throughput
screening methods for identifying new antiviral drugs against BWT
agents; 2) develop rapid, sensitive, and specific detection systems
for identifying infectious BWT viruses and antibodies in infected
persons; and 3) utilize state-of-the-art siRNA technology to identify
host factors that could serve as the basis for development of new
classes of antivirals with broader reactivity and less likelihood
of genetic evasion by the viral pathogen. This research will meet
critical, immediate needs for viral biodefense by accelerating
the development of antivirals, diagnostics, and vaccine development
and by moving much of this viral BWT research into the low-containment
(BSL2) arena. Our project will also provide important new tools
for basic research on BWT viruses, such as the identification of
cellular receptors and mechanisms of pathogenesis, which will benefit
both basic and applied virology research now and in the future.
|